AlzeCure Pharma AB Cash Flow Statement

Financials in millions SEK. Fiscal year is January - December.

Millions SEK. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2020 - 2017
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2020 - 2017
Net Income	-47.65	-35.23	-37.17	-56.24	-77.78	Upgrade
Depreciation & Amortization	1.27	0.29	0.48	0.57	0.58	Upgrade
Change in Accounts Receivable	0.04	-0.04	-	-41.92	0.01	Upgrade
Change in Accounts Payable	1.47	-0	-2.16	-1.13	2.01	Upgrade
Change in Other Net Operating Assets	10.29	-0.15	41.91	-1.19	4.55	Upgrade
Operating Cash Flow	-34.59	-35.12	3.06	-99.91	-70.64	Upgrade
Capital Expenditures	-	-0.12	-	-	-0.05	Upgrade
Investment in Securities	-	-	0.01	-	-	Upgrade
Investing Cash Flow	-	-0.12	0.01	-	-0.05	Upgrade
Long-Term Debt Repaid	-1.08	-	-	-	-	Upgrade
Net Debt Issued (Repaid)	-1.08	-	-	-	-	Upgrade
Issuance of Common Stock	58.56	44.55	0.42	94.07	-	Upgrade
Other Financing Activities	-4.06	-6.91	0.04	-10.32	-	Upgrade
Financing Cash Flow	53.43	37.65	0.46	83.75	-	Upgrade
Net Cash Flow	18.84	2.4	3.52	-16.16	-70.69	Upgrade
Free Cash Flow	-34.59	-35.25	3.06	-99.91	-70.69	Upgrade
Free Cash Flow Per Share	-0.34	-0.46	0.05	-2.10	-1.87	Upgrade
Cash Interest Paid	0.26	0.02	0.01	0	0	Upgrade
Levered Free Cash Flow	-15.33	-22.63	-26.2	-36.58	-41.75	Upgrade
Unlevered Free Cash Flow	-15.15	-22.62	-26.2	-36.57	-41.75	Upgrade
Change in Working Capital	11.8	-0.18	39.75	-44.24	6.57	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.